Mantosh Kumar Satapathy | Pharmacology | Best Researcher Award

Published on by World Top Scientists

Dr. Mantosh Kumar Satapathy | Pharmacology | Best Researcher Award

Mantosh Kumar Satapathy  | Taipei Medical University | Taiwan

Dr. Mantosh Kumar Satapathy, Ph.D., is a distinguished biomedical scientist, biotechnologist, pharmacologist, and tissue engineer based at Taipei Medical University, Taiwan, with extensive international experience in pharmacology, biomedical engineering, and nanobiotechnology. He earned his Ph.D. in Biomedical Materials and Tissue Engineering from Taipei Medical University, following an M.Tech. in Industrial Biotechnology and a Bachelor of Pharmacy, establishing a strong foundation in translational medical research. Dr. Satapathy has held postdoctoral and research fellow positions at leading institutions, leading projects on advanced nanodrug delivery systems, stem cell therapeutics, tissue engineering, and nanoformulation design, while supervising molecular biology laboratories and mentoring junior researchers. His research contributions include the development of stimuli-responsive nanocomposite hydrogels for orthopedic and skin tissue regeneration, engineering of nanocurcumin-based formulations for targeted therapies, and investigations into gene regulation and drug repurposing in cancer and skin pathologies. He has published extensively in high-impact peer-reviewed journals, contributed to international book chapters, co-invented a U.S. patent, and presented his work at global scientific conferences. Dr. Satapathy’s work has been recognized with multiple Outstanding Postdoctoral Researcher awards, and he actively serves as a peer reviewer, reflecting his leadership in the scientific community. He is a life member of professional organizations, has completed specialized research training in molecular diagnostics and biotechnology, and continues to advance interdisciplinary research that bridges fundamental science and clinical application, demonstrating exceptional impact in biomedical innovation.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Banerjee, P., Satapathy, M., Mukhopahayay, A., & Das, P. (2014). Leaf extract mediated green synthesis of silver nanoparticles from widely available Indian plants: Synthesis, characterization, antimicrobial property and toxicity analysis. Bioresources and Bioprocessing, 1(1), 3.

2. Satapathy, M. K., Yen, T. L., Jan, J. S., Tang, R. D., Wang, J. Y., Taliyan, R., & Yang, C. H. (2021). Solid lipid nanoparticles (SLNs): An advanced drug delivery system targeting brain through BBB. Pharmaceutics, 13(8), 1183.

3. Satapathy, M. K., & Das, P. (2014). Optimization of crystal violet dye removal using novel soil-silver nanocomposite as nanoadsorbent using response surface methodology. Journal of Environmental Chemical Engineering, 2(1), 708–714.

4. Satapathy, M. K., Banerjee, P., & Das, P. (2015). Plant-mediated synthesis of silver-nanocomposite as novel effective azo dye adsorbent. Applied Nanoscience, 5(1), 1–9.

5. Satapathy, M. K., Nyambat, B., Chiang, C. W., Chen, C. H., Wong, P. C., Ho, P. H., … (2018). A gelatin hydrogel-containing nano-organic PEI–Ppy with a photothermal responsive effect for tissue engineering applications. Molecules, 23(6), 1256.

Laura Machin Galarza | Pharmacology | Young Scientist Award

Published on by World Top Scientists

Assist. Prof. Dr. Laura Machin Galarza | Pharmacology | Young Scientist Award

Laura Machin Galarza | University of Havana | Cuba

Dr. Laura Machin Galarza is an Assistant Professor and Researcher at the Institute of Pharmacy and Foods, University of Havana, specializing in pharmaceutical sciences and parasitology. She holds a Bachelor’s, Master’s, and Doctorate in Pharmaceutical Sciences from the University of Havana, where her academic journey has been marked by excellence and commitment to translational research. Dr. Machin has undertaken prestigious research stays at institutions in Austria, Germany, China, and Cuba, contributing to international collaborations focused on pharmacology, toxicology, and biopharmaceutical innovation. Her professional experience includes leadership in multidisciplinary projects exploring the antiprotozoal and antileishmanial potential of natural and synthetic compounds, advanced drug delivery systems, and pharmacological recycling strategies. She has authored multiple peer-reviewed publications in high-impact journals such as Pharmaceuticals, Molecules, and Experimental Parasitology, demonstrating expertise in medicinal chemistry and drug development. Dr. Machin’s work has been recognized through contributions to award-winning research honored by the Cuban Academy of Sciences. She actively serves in academic editorial processes, participates in professional scientific societies, and holds certifications that reflect her dedication to research excellence, innovation, and scientific leadership in the field of pharmaceutical sciences.

Profiles: Google Scholar | Scopus 

Featured Publications

1. B. Salehi, L. Machin, L. Monzote, J. Sharifi-Rad, S. M. Ezzat, M. A. Salem, et al., “Therapeutic potential of quercetin: new insights and perspectives for human health,” ACS Omega, vol. 5, no. 20, pp. 11849–11872, 2020.

2. B. Tamargo, L. Monzote, A. Piñón, L. Machín, M. García, R. Scull, W. N. Setzer, “In vitro and in vivo evaluation of essential oil from Artemisia absinthium L. formulated in nanocochleates against cutaneous leishmaniasis,” Medicines, vol. 4, no. 2, p. 38, 2017.

3. L. Machín, R. Nápoles, L. Gille, L. Monzote, “Leishmania amazonensis response to artemisinin and derivatives,” Parasitology International, vol. 80, p. 102218, 2021.

4. G. Geroldinger, M. Tonner, J. Quirgst, M. Walter, S. De Sarkar, L. Machín, et al., “Activation of artemisinin and heme degradation in Leishmania tarentolae promastigotes: a possible link,” Biochemical Pharmacology, vol. 173, p. 113737, 2020.

5. L. Machín, B. Tamargo, A. Piñón, R. C. Atíes, R. Scull, W. N. Setzer, L. Monzote, “Bixa orellana L. (Bixaceae) and Dysphania ambrosioides (L.) Mosyakin & Clemants (Amaranthaceae) essential oils formulated in nanocochleates against Leishmania amazonensis,” Molecules, vol. 24, no. 23, p. 4222, 2019.

Lixin Yan | Pharmacology | Best Researcher Award

Published on by World Top Scientists

Mrs. Lixin Yan | Pharmacology | Best Researcher Award

Medical manager | Sinocelltech Ltd | China

Mrs. Lixin Yan is an accomplished medical manager with extensive experience in clinical research, specializing in oncology, infectious diseases, vaccines, and metabolic products. Over the years, she has led multiple Phase I–III clinical trials, contributing to protocol development, medical monitoring, feasibility assessment, and regulatory submissions. Her work has been instrumental in the clinical development of innovative therapies, including PD-1 inhibitors, EGFR-targeted treatments, HPV and COVID-19 vaccines, insulin, and GLP-1 products. She demonstrates strong expertise in GCP compliance, regulatory processes, and cross-functional team collaboration, ensuring high-quality research outcomes. Mrs. Yan has published impactful peer-reviewed articles, including first-author papers, highlighting her ability to generate reliable clinical evidence. Her dedication to advancing medical science through rigorous research and mentorship reflects her potential to lead future high-impact studies. Her measurable research impact is demonstrated through 68 citations, 5 documents, and an h-index of 4 according to Scopus.

Profile: Scopus

Featured Publications

1. L. Yan, J. Yi, D. Liu, J. Li, A. A. H. Baidoo, and L. Xie, “Efficacy and safety of SARS-CoV-2 neutralizing antibody, SCTA01, in high-risk outpatients diagnosed with COVID-19: A Phase II clinical trial,” Contemporary Clinical Trials Communications, 2025.

Ksenia Blinova | Pharmacology | Best Researcher Award

Published on by World Top Scientists

Dr. Ksenia Blinova | Pharmacology | Best Researcher Award

Associate Director at US Food and Drug Administration, United States

Dr. Ksenia Blinova, Ph.D., is the Associate Director for the Division of Applied Regulatory Science at the U.S. Food and Drug Administration, where she leads innovative research, regulatory reviews, and scientific consultations that advance translational science in support of public health. With a strong academic foundation in physics, mathematics, and cardiac electrophysiology, she has built a distinguished career focused on bridging fundamental science with regulatory applications. Since joining the FDA as a Commissioner’s Fellow, Dr. Blinova has held key leadership roles, including Deputy Director of the Division of Biomedical Physics, where she led multidisciplinary teams in developing over forty regulatory science tools that improved the evaluation of medical devices across fields such as cardiology, neurostimulation, diagnostics, and patient monitoring. Her career reflects a unique combination of scientific excellence, leadership, and commitment to advancing safe and effective medical products, making her an influential figure in the field of regulatory science.

Professional Profile 

Scopus Profile | ORCID Profile 

Education

Dr. Ksenia Blinova earned her undergraduate and doctoral degrees in Physics and Mathematics from Moscow State University, where she developed a strong foundation in quantitative sciences and analytical problem-solving. She further advanced her academic journey through a postdoctoral fellowship at the National Heart, Lung, and Blood Institute at the National Institutes of Health. Her research during this period centered on cardiac electrophysiology and metabolism, areas that deepened her expertise in biomedical applications of physical sciences. This educational trajectory not only equipped her with advanced technical knowledge but also gave her a unique interdisciplinary perspective that integrates rigorous physics and mathematical methodologies with life sciences and clinical research. Her educational background has been pivotal in shaping her ability to address complex regulatory and scientific challenges, contributing to her capacity for innovation and leadership in translational science and regulatory policy at the intersection of medicine, technology, and public health.

Experience

Dr. Blinova has built a distinguished career at the U.S. Food and Drug Administration, beginning as a Commissioner’s Fellow and progressing to influential leadership roles. As Deputy Director of the Division of Biomedical Physics in the Center for Devices and Radiological Health, she guided a multidisciplinary team in creating innovative regulatory science tools that addressed critical challenges in medical device safety and effectiveness. Her leadership was instrumental in developing methods and resources for fields such as cardiology, neurostimulation, ophthalmology, in-vivo diagnostics, and advanced patient monitoring. Currently serving as Associate Director for the Division of Applied Regulatory Science in the Office of Clinical Pharmacology, she oversees research, scientific consultations, and regulatory reviews that support the FDA’s translational science priorities. Through these roles, she has combined her technical expertise with strategic vision, ensuring that scientific advancements translate into practical regulatory applications that safeguard patient health and promote medical innovation.

Research Focus

Dr. Blinova’s research focuses on advancing translational and regulatory science to accelerate the safe and effective delivery of medical products to patients. Her early work in cardiac electrophysiology and metabolism provided insights into fundamental mechanisms of heart function, laying the groundwork for her later contributions in biomedical physics and device evaluation. At the FDA, she has led research efforts that integrate computational modeling, experimental studies, and regulatory tool development to address complex safety and efficacy challenges in medical devices and drug-device combinations. Her team has developed innovative approaches to evaluate technologies in cardiology, neurostimulation, electrical safety, diagnostics, and patient monitoring, ensuring that regulatory science keeps pace with rapid technological advances. By bridging basic science, applied research, and policy, her work exemplifies the role of regulatory science in translating innovation into tangible benefits for patients and healthcare systems, while maintaining a focus on safety, effectiveness, and public health impact.

Award and Honor

Throughout her career, Dr. Blinova has been recognized for her leadership, innovation, and contributions to regulatory science. Her accomplishments include guiding the development of over forty regulatory tools that have had a lasting impact on how medical devices are assessed for safety and effectiveness. These achievements reflect not only her scientific expertise but also her ability to collaborate across disciplines to solve pressing healthcare challenges. Her recognition within the FDA and broader scientific community underscores her role as a leader who consistently advances the field of translational science. Honors and awards in her career highlight her success in bridging science and regulation, her dedication to patient safety, and her influence in shaping modern approaches to medical product evaluation. These distinctions serve as a testament to her sustained contributions, her commitment to innovation, and her growing impact as a respected figure in regulatory and biomedical research.

Publication Top Notes

  • Title: Nonclinical Human Cardiac New Approach Methodologies (NAMs) Predict Vanoxerine-Induced Proarrhythmic Potential
    Authors: M. Iveth Garcia, Bhavya Bhardwaj, Keri Dame, Verena Charwat, Brian A. Siemons, Ishan Goswami, Omnia A. Ismaiel, Sabyasachy Mistry, Tromondae K. Feaster, Kevin E. Healy, et al.
    Year: 2025

  • Title: In Vitro Assay Development to Study Pulse Field Ablation Outcome Using Solanum Tuberosum
    Authors: Akshay Narkar, Abouzar Kaboudian, Yasaman Ardeshirpour, Maura Casciola, Tromondae Feaster, Ksenia Blinova
    Year: 2024
    Citations: 2

  • Title: Nonclinical evaluation of chronic cardiac contractility modulation on 3D human engineered cardiac tissues
    Authors: Tromondae K. Feaster, Jourdan K. Ewoldt, Anna Avila, Maura Casciola, Akshay Narkar, Christopher S. Chen, Ksenia Blinova
    Year: 2024

  • Title: Comprehensive Collection of Current Methods for Contractility and Electrophysiology Recordings in Human Cardiac Cells
    Authors: Ksenia Blinova, J. Pierson, A. Narkar
    Year: 2023

  • Title: Human in vitro assay for irreversible electroporation cardiac ablation
    Authors: Maura Casciola, Tromondae K. Feaster, M. J. Caiola, D. Keck, Ksenia Blinova
    Year: 2023

  • Title: Acute effects of cardiac contractility modulation stimulation in conventional 2D and 3D human induced pluripotent stem cell-derived cardiomyocyte models
    Authors: Tromondae K. Feaster, N. Feric, I. Pallotta, A. Narkar, M. Casciola, M. P. Graziano, R. Aschar-Sobbi, Ksenia Blinova
    Year: 2022

  • Title: Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
    Authors: Tromondae K. Feaster, Maura Casciola, Akshay Narkar, Ksenia Blinova
    Year: 2022

  • Title: Human in vitro neurocardiac coculture (iv NCC) assay development for evaluating cardiac contractility modulation
    Authors: Akshay Narkar, Tromondae K. Feaster, Maura Casciola, Ksenia Blinova
    Year: 2022

  • Title: Human cardiomyocytes are more susceptible to irreversible electroporation by pulsed electric field than human esophageal cells
    Authors: Maura Casciola, Devin Keck, Tromondae K. Feaster, Ksenia Blinova
    Year: 2022

  • Title: Chronic Cardiotoxicity Assays Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs)
    Authors: Akshay Narkar, James M. Willard, Ksenia Blinova
    Year: 2022

  • Title: Cardiovascular medical devices: Regulatory science research overview in the office of science and engineering laboratories (OSEL) at the food and drug administration (FDA)
    Authors: K. Aycock, Ksenia Blinova, M. Casciola, B. Craven, M. Di Prima, G. D’Souza, N. Duraiswamy, M. Farahmand, P. Hariharan, L. Herbertson, et al.
    Year: 2021

  • Title: Acute effects of cardiac contractility modulation on human induced pluripotent stem cell–derived cardiomyocytes
    Authors: Tromondae K. Feaster, Maura Casciola, Akshay Narkar, Ksenia Blinova
    Year: 2021

Conclusion

Dr. Ksenia Blinova has demonstrated exceptional expertise and leadership in translational and regulatory science, particularly in the evaluation and development of cardiac therapies and medical devices. Her extensive body of research, including numerous high-impact publications on human in vitro cardiac models, contractility modulation, and electroporation assays, reflects a consistent focus on innovative approaches that bridge fundamental science with practical clinical and regulatory applications. She has led multidisciplinary teams to develop tools and methodologies that enhance patient safety, accelerate medical innovation, and provide reliable scientific evidence for regulatory decisions. Her work not only advances the understanding of cardiac electrophysiology and device performance but also sets new standards for predictive, nonclinical cardiac research. Overall, Dr. Blinova’s contributions exemplify the qualities of a pioneering researcher whose scientific rigor, leadership, and commitment to public health make her highly deserving of recognition in any Best Researcher Award.

Lichun Zhao | Pharmacology | Best Researcher Award

Published on by World Top Scientists

Prof. Dr. Lichun Zhao | Pharmacology | Best Researcher Award

Guizhou University of Traditional Chinese Medicine, China

Prof. Dr. Lichun Zhao is a distinguished researcher and academic leader specializing in trace elements, traditional medicine, and health development. He serves as a doctoral supervisor, director of research centers and laboratories, and executive editor in chief of Trace Elements and Health Research, while holding key leadership roles in national and regional scientific associations. Recognized with numerous prestigious honors, he has successfully led major national and international projects, secured innovative medicine approvals, and contributed to product development. His prolific output includes over two hundred publications, highly cited SCI papers, multiple monographs, patents, and software copyrights, reflecting both scientific innovation and practical application. He has also been honored with multiple science and technology awards, underscoring the impact of his research. Committed to advancing both scholarship and healthcare, Prof. Zhao exemplifies excellence in integrating academic research, innovation, and leadership, making him a highly influential figure in his field.

Professional Profile 

Scopus Profile

Education

Prof. Dr. Lichun Zhao earned his Ph.D. in a field closely related to trace elements, medicine, and health sciences, building a solid academic foundation for his future research. Following his doctoral studies, he pursued postdoctoral training at Hong Kong Baptist University, where he broadened his expertise and gained valuable international research exposure. His educational journey reflects a strong emphasis on both traditional medicine and modern scientific approaches, allowing him to bridge classical knowledge with contemporary methodologies. By combining advanced laboratory techniques with deep understanding of traditional Chinese medicine, he has cultivated a unique academic profile that continues to drive his research innovations. His educational background not only prepared him for his roles in academia and research but also established his credentials as a mentor for doctoral students and an authoritative voice in integrating traditional practices with modern scientific frameworks.

Experience

Prof. Dr. Zhao has accumulated extensive academic and professional experience through his multiple leadership roles and active engagement in research. He serves as a doctoral supervisor, guiding and mentoring the next generation of researchers, while simultaneously holding positions as director of the Research Department and the Center for Trace Elements and Health Development at Guizhou University of Chinese Medicine. Beyond his university roles, he directs major laboratories in Guizhou and Guangxi, leading innovation in endangered medicinal resources. His editorial work as executive editor in chief of Trace Elements and Health Research further demonstrates his commitment to advancing scholarly communication. In addition, he actively contributes to national scientific development as a project evaluation expert for significant research foundations and technology awards. Through these experiences, Prof. Zhao has built a career that integrates research, leadership, and service, positioning him as both a pioneering scientist and an influential academic administrator.

Research Focus

The core of Prof. Dr. Zhao’s research lies in the intersection of trace elements, traditional Chinese medicine, and health development. His work emphasizes the exploration of medicinal resources, the development of innovative treatments, and the application of modern scientific tools such as big data and artificial intelligence to healthcare research. He has led numerous national and international projects aimed at advancing understanding of trace elements in human health, as well as developing standardized, evidence-based approaches to traditional medicine. A significant part of his focus is dedicated to the preservation and innovation of endangered medicinal materials, ensuring sustainable resources for future therapeutic use. His achievements include obtaining clinical approvals for new medicine, producing certified products, and publishing influential studies recognized globally. Prof. Zhao’s research is notable for its ability to combine ancient knowledge with modern technology, creating novel solutions that enhance healthcare outcomes and scientific advancement.

Award and Honor

Prof. Dr. Zhao has been widely recognized for his scientific excellence and leadership with numerous national and regional awards. He was the first to receive the prestigious National Youth Qihuang Scholar distinction and has been selected for Hong Kong’s “Excellent Talent Plan.” His honors include recognition as an Outstanding Scholar in Guangxi, a leader of high-level innovation teams, and a candidate in talent development initiatives such as the “Ten Hundred Thousand Talents Project.” He has also received the Guangxi Youth Science and Technology Award and multiple provincial science and technology prizes, including the Guangxi Science and Technology Progress Award and the Jilin Province Natural Science Award. His contributions have further been acknowledged through the China Industry-University-Research Cooperation Innovation Award. Collectively, these distinctions highlight not only his research excellence but also his role as an innovator and leader whose work has had profound impact in both academic and applied scientific fields.

Publications Top Notes

  • Title: The close relationship between trace elements (Cu, Fe, Zn, Se, Rb, Si, Cr, and V) and Alzheimer’s disease: Research progress and insights
    Authors: Zhao Lichun et al.
    Year: 2025

  • Title: Bacteriostatic activity and mechanism of minerals containing rubidium
    Authors: Zhao Lichun et al.
    Year: 2025

  • Title: Traditional Chinese medicine in chronic rhinosinusitis: Mechanisms and postoperative recovery
    Authors: Zhao Lichun et al.
    Year: 2025
    Citations: 3

  • Title: Rosmarinic acid promotes mitochondrial fission and induces ferroptosis in triple-negative breast cancer cells
    Authors: Zhao Lichun et al.
    Year: 2025
    Citations: 13

  • Title: Interfacial Stabilization through MOF-Polymer Core-Shell Design: Ultraefficient, Stable and Recyclable Enzymatic Microreactors
    Authors: Zhao Lichun et al.
    Year: 2025

  • Title: Rubidium salt can effectively relieve the symptoms of DSS-induced ulcerative colitis
    Authors: Zhao Lichun et al.
    Year: 2024
    Citations: 22

Conclusion

The reviewed publications of Prof. Dr. Lichun Zhao reflect a strong and diverse research portfolio spanning trace elements, traditional Chinese medicine, cancer biology, inflammatory diseases, and innovative material science applications. His works demonstrate both depth in exploring mechanisms of disease and breadth in applying interdisciplinary approaches to health solutions. The range of topics covered—from Alzheimer’s disease and rhinosinusitis to breast cancer and ulcerative colitis—highlights his ability to integrate traditional medicine knowledge with modern biomedical and technological advances. The citations already received for some of these recent studies, particularly in high-impact areas such as cancer research and therapeutic innovations, indicate growing recognition of his contributions within the scientific community. Overall, his research achievements showcase academic rigor, innovation, and practical significance, further strengthening his candidacy for recognition through prestigious research awards.